FINZALA

This brand name is authorized in United States.

Active ingredients

The drug FINZALA contains a combination of these active pharmaceutical ingredients (APIs):

`1`	17 alpha-Ethinylestradiol UNII `423D2T571U` - ETHINYL ESTRADIOL
	Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.
	Read more about 17 alpha-Ethinylestradiol
`2`	Noradrenaline UNII `9S44LIC7OJ` - NORETHINDRONE ACETATE
	Noradrenaline provides a strong stimulation of alpha receptors in blood vessels at which these are counter-extracted. Noradrenaline also has an effect on beta-1 receptors in the heart leading to a positive inotropic and initially positive chronotropic effect. The increase in blood pressure may cause a reflex reduction in heart rate.
	Read more about Noradrenaline

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FINZALA Chewable tablet, Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	0093-3476, 0093-3525, 0093-8210

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.